Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma

[1]  藤倉雄二,et al.  わが国における成人市中肺炎原因微生物についてのsystematic review/meta‐analysis , 2016 .

[2]  Chi-Ping Day,et al.  Preclinical Mouse Cancer Models: A Maze of Opportunities and Challenges , 2015, Cell.

[3]  M. Junttila,et al.  Translational value of mouse models in oncology drug development , 2015, Nature Medicine.

[4]  Sridhar Ramaswamy,et al.  Patient-derived models of acquired resistance can identify effective drug combinations for cancer , 2014, Science.

[5]  Charles Swanton,et al.  Cancer: evolution within a lifetime. , 2014, Annual review of genetics.

[6]  M. Esteller,et al.  Modeling lung cancer evolution and preclinical response by orthotopic mouse allografts. , 2014, Cancer research.

[7]  S. Peters,et al.  Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions. , 2014, Cancer treatment reviews.

[8]  Emma R. Andersson,et al.  Therapeutic modulation of Notch signalling — are we there yet? , 2014, Nature Reviews Drug Discovery.

[9]  C. Gridelli,et al.  ALK inhibitors in the treatment of advanced NSCLC. , 2014, Cancer treatment reviews.

[10]  R. Pirker.  Novel drugs against non-small-cell lung cancer. , 2014, Current opinion in oncology.

[11]  M. Krasnow,et al.  Alveolar progenitor and stem cells in lung development, renewal and cancer , 2014, Nature.

[12]  C. Swanton,et al.  The evolution of the unstable cancer genome. , 2014, Current opinion in genetics & development.

[13]  Rolf Kaiser,et al.  Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. , 2014, The Lancet. Oncology.

[14]  B. Leitinger.  Discoidin domain receptor functions in physiological and pathological conditions. , 2014, International review of cell and molecular biology.

[15]  Y. Yashiro‐Ohtani,et al.  Identifying direct Notch transcriptional targets using the GSI-washout assay. , 2014, Methods in molecular biology.

[16]  M. Barbacid,et al.  Identification of cancer initiating cells in K-Ras driven lung adenocarcinoma , 2013, Proceedings of the National Academy of Sciences.

[17]  S. Lam,et al.  Genetic alterations defining NSCLC subtypes and their therapeutic implications. , 2013, Lung cancer.

[18]  E. Puré,et al.  Notch1 is required for Kras-induced lung adenocarcinoma and controls tumor cell survival via p53. , 2013, Cancer research.

[19]  Corbin E. Meacham,et al.  Tumour heterogeneity and cancer cell plasticity , 2013, Nature.

[20]  Chuong D. Hoang,et al.  A rare population of CD24(+)ITGB4(+)Notch(hi) cells drives tumor propagation in NSCLC and requires Notch3 for self-renewal. , 2013, Cancer cell.

[21]  Jie Yang,et al.  Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: a systematic review with meta-analysis. , 2013, Lung cancer.

[22]  H. Cai,et al.  Discoidin domain receptor 1 is associated with poor prognosis of non-small cell lung cancer and promotes cell invasion via epithelial-to-mesenchymal transition , 2013, Medical Oncology.

[23]  D. Beer,et al.  C-Reactive Protein Downregulates TRAIL Expression in Human Peripheral Monocytes via an Egr-1–Dependent Pathway , 2013, Clinical Cancer Research.

[24]  Ke Ding,et al.  Discovery and optimization of 3-(2-(Pyrazolo[1,5-a]pyrimidin-6-yl)ethynyl)benzamides as novel selective and orally bioavailable discoidin domain receptor 1 (DDR1) inhibitors. , 2013, Journal of medicinal chemistry.

[25]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[26]  P. Jänne,et al.  New targetable oncogenes in non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  R. Carano,et al.  Blocking NRG1 and Other Ligand-Mediated Her4 Signaling Enhances the Magnitude and Duration of the Chemotherapeutic Response of Non–Small Cell Lung Cancer , 2013, Science Translational Medicine.

[28]  Lucio Crinò,et al.  Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. , 2013, The Lancet. Oncology.

[29]  Edward J. Kim,et al.  Anti-DLL4 Has Broad Spectrum Activity in Pancreatic Cancer Dependent on Targeting DLL4-Notch Signaling in Both Tumor and Vasculature Cells , 2012, Clinical Cancer Research.

[30]  Manuel Serrano,et al.  Therapeutic effect of γ-secretase inhibition in KrasG12V-driven non-small cell lung carcinoma by derepression of DUSP1 and inhibition of ERK. , 2012, Cancer cell.

[31]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[32]  Andrew L. Kung,et al.  A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response , 2012, Nature.

[33]  Christopher A. Miller,et al.  VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. , 2012, Genome research.

[34]  Celina G. Kleer,et al.  Discoidin domain receptor tyrosine kinases: new players in cancer progression , 2012, Cancer and Metastasis Reviews.

[35]  F. Lecanda,et al.  Inhibition of Collagen Receptor Discoidin Domain Receptor-1 (DDR1) Reduces Cell Survival, Homing, and Colonization in Lung Cancer Bone Metastasis , 2012, Clinical Cancer Research.

[36]  Satoru Miyano,et al.  Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. , 2012, Cancer research.

[37]  F. Aoudjit,et al.  Discoidin domain receptor 1 expression in activated T cells is regulated by the ERK MAP kinase signaling pathway , 2011, Journal of cellular biochemistry.

[38]  C. Chatziantoniou,et al.  Discoidin domain receptor 1 is a major mediator of inflammation and fibrosis in obstructive nephropathy. , 2011, The American journal of pathology.

[39]  D. Tuveson,et al.  C-Raf is required for the initiation of lung cancer by K-Ras(G12D). , 2011, Cancer discovery.

[40]  M. Barbacid,et al.  c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma. , 2011, Cancer cell.

[41]  So-Young Hwang,et al.  DDR1 Receptor Tyrosine Kinase Promotes Prosurvival Pathway through Notch1 Activation* , 2011, The Journal of Biological Chemistry.

[42]  S. Lippman,et al.  Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  K. Jang,et al.  Discoidin domain receptor 1 is associated with poor prognosis of non-small cell lung carcinomas. , 2010, Oncology reports.

[44]  M. Barbacid,et al.  A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. , 2010, Cancer cell.

[45]  H. Hakonarson,et al.  ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.

[46]  Bin Fang,et al.  A chemical and phosphoproteomic characterization of dasatinib action in lung cancer , 2010, Nature chemical biology.

[47]  Richard Durbin,et al.  Fast and accurate long-read alignment with Burrows–Wheeler transform , 2010, Bioinform..

[48]  G. Pelosi,et al.  Alterations of the Notch pathway in lung cancer , 2009, Proceedings of the National Academy of Sciences.

[49]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[50]  A. Honegger,et al.  The human combinatorial antibody library HuCAL GOLD combines diversification of all six CDRs according to the natural immune system with a novel display method for efficient selection of high-affinity antibodies. , 2008, Journal of molecular biology.

[51]  Laura A. Sullivan,et al.  Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer , 2007, Cell.

[52]  Gordon K. Smyth,et al.  Use of within-array replicate spots for assessing differential expression in microarray experiments , 2005, Bioinform..

[53]  J. Mesirov,et al.  An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis , 2005, Nature Genetics.

[54]  Jill P. Mesirov,et al.  Consensus Clustering: A Resampling-Based Method for Class Discovery and Visualization of Gene Expression Microarray Data , 2003, Machine Learning.

[55]  Manuel Serrano,et al.  Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. , 2003, Cancer cell.

[56]  W. Hahn,et al.  Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells , 2002, Nature Medicine.

[57]  A. Berns,et al.  Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer , 2001, Nature Genetics.

[58]  T. Pawson,et al.  Discoidin Domain Receptor 1 Tyrosine Kinase Has an Essential Role in Mammary Gland Development , 2001, Molecular and Cellular Biology.

[59]  R. Hoffman.  Clinically accurate orthotopic mouse models of cancer. , 2001, Methods in molecular medicine.

[60]  R. Kageyama,et al.  Basic helix-loop-helix transcription factors regulate the neuroendocrine differentiation of fetal mouse pulmonary epithelium. , 2000, Development.

[61]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[62]  M. Barbacid,et al.  Multiple tyrosine protein kinases in rat hippocampal neurons: isolation of Ptk-3, a receptor expressed in proliferative zones of the developing brain. , 1994, Proceedings of the National Academy of Sciences of the United States of America.